NEXIEN BIOPHARMA, INC.
NEXIEN BIOPHARMA, INC. (NXEN): 3 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.9 months
D/E -1.02 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for NEXIEN BIOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7K
Cash
$8K
Quarterly Burn
$13K
Runway
1.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cannabinoid receptor modulators and/or terpenes | Preclinical |
| dysport | Approved |
| parenteral-delivered formulations | Preclinical |
Frequently asked questions
How many drug candidates are in NEXIEN BIOPHARMA, INC.'s pipeline?
NEXIEN BIOPHARMA, INC. (NXEN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEXIEN BIOPHARMA, INC.'s lead drug candidate?
NEXIEN BIOPHARMA, INC.'s most advanced tracked candidate is cannabinoid receptor modulators and/or terpenes (Preclinical) for Acute treatment situations during exposure to organophosphorus nerve agents and/or organophosphorus insecticides.
What is NEXIEN BIOPHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEXIEN BIOPHARMA, INC. has approximately 1.9 months of cash runway.
What is NEXIEN BIOPHARMA, INC.'s market capitalization?
NEXIEN BIOPHARMA, INC.'s market capitalization is approximately $7K.
Who is the CEO of NEXIEN BIOPHARMA, INC.?
Mr. Richard S. Greenberg is the chief executive officer of NEXIEN BIOPHARMA, INC. (NXEN).
Get the full picture on NEXIEN BIOPHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.